Brachytherapy Market Highlights

• Global brachytherapy market revenue is poised to garner USD 1,785.9 million by 2032 with a CAGR of 7.8% from 2024 to 2032
• North America Brachytherapy market value occupied around USD 410.6 million in 2023
• Asia-Pacific brachytherapy market growth will record a CAGR of more than 8.6% from 2024 to 2032
• Among dosage type, the high-dose rate (HDR) brachytherapy sub-segment generated 71% of the market share in 2023
• Based on product, the applicators & afterloaders sub-segment generated 44% of market share in 2023
• Based on product, the prostate cancer sub-segment gathered USD 301.1 million revenue in 2023
• Growing demand for minimally invasive treatments is the brachytherapy market trend that fuels the industry demand

Brachytherapy is a type of internal radiation therapy in which radioactive sources are inserted directly into or adjacent to a tumor. This tailored technique gives a high dosage of radiation to the target location while limiting exposure to healthy tissues nearby. It is widely used to treat prostate, cervical, and breast cancer. Depending on the location and type of tumor, intracavitary, interstitial, or surface applicators may be employed. Brachytherapy is typically used in conjunction with other treatments, such as surgery or external beam radiation, to improve overall efficacy.

Global Brachytherapy Market Dynamics

Market Drivers

• Increasing prevalence of cancer, particularly prostate and breast cancer
• Technological advancements improving treatment precision and outcomes
• Growing adoption of outpatient procedures and personalized medicine

Market Restraints

• High cost of brachytherapy equipment and treatments
• Limited availability of trained medical professionals
• Regulatory hurdles and reimbursement issues in some regions

Market Opportunities

• Development of innovative brachytherapy techniques and devices
• Expansion into emerging markets with rising cancer incidences
• Integration with other cancer therapies for enhanced treatment efficacy

Brachytherapy Market Report Coverage

Brachytherapy Market Insights

Technological developments and R&D by key industry competitors are some of the proper growth factors. For instance, Salutaris Varian Medical Systems launched the TrueBeam STx, a new brachytherapy system, in May 2023. The TrueBeam STx is a high-dose rate (HDR) brachytherapy system that uses a linear accelerator to deliver large amounts of radiation to tumors. Expanding the use of these developments, as well as the availability of good payment approaches in developing countries, are necessary to further fuel the growth of the brachytherapy market.

The high cost of brachytherapy equipment and treatments has a substantial impact on the brachytherapy market. This financial barrier limits the use of brachytherapy, particularly in low- and middle-income countries, impeding market expansion.

According to International Agency for Research on Cancer, there were about 20 million new cancer cases and nearly ten million cancer-related deaths in 2022. According to demographic forecasts, the annual number of new cancer cases is expected to reach 35 million by 2050, a 77% rise from 2022. According to the American brachytherapy Society, the security and viability of brachytherapy treatment over conventional cancer growth treatments, such as chemotherapy and medical procedures, is expected to benefit the market.

Brachytherapy Market Segmentation

The worldwide market for brachytherapy is split based on dosage type, product, application, and geography.

Brachytherapy Dosage Types

• High-Dose Rate (HDR) Brachytherapy
• Low-Dose Rate (LDR) Brachytherapy

According to the brachytherapy industry analysis, high-dose rate (HDR) brachytherapy dosage type dominates market because of its ability to deliver precise, high doses of radiation to cancerous tissues while minimizing exposure to healthy tissues. This targeted strategy enhances treatment outcomes, lowers side effects, and shortens treatment time. HDR brachytherapy's adaptability in treating a number of diseases, such as cervical, prostate, and breast cancer, contributes to its widespread use.

Brachytherapy Products

• Seeds
• Applicators & Afterloaders
• Electronic Brachytherapy

The applicators & afterloaders segment is the largest product category in the brachytherapy market. These technologies enhance therapeutic precision and patient results while minimizing exposure to nearby healthy tissues. Their technological advancements and expanded use in the treatment of various cancers contribute to their market dominance. Furthermore, the rising prevalence of cancer and the growing preference for minimally invasive procedures contribute to the segment's significant market share.

Brachytherapy Applications

• Prostate Cancer
• Gynaecological Cancer
• Breast Cancer
• Others

According to the brachytherapy market forecast, prostate cancer is the most common application for brachytherapy. For instance, in March 2023, the FDA authorized the TomoTherapy Hi-Art brachytherapy system for the treatment of prostate cancer. The TomoTherapy Hi-Art system is a robotic brachytherapy device that employs a CT scanner to image the tumor before delivering radiation in a precise and targeted manner. Brachytherapy includes inserting radioactive seeds directly into or near the prostate, which provides high-dose radiation with fewer side effects than external beam radiation. This medication has showed promise in slowing cancer progression and maintaining quality of life. As a result of the high prevalence of prostate cancer and the demonstrated benefits of brachytherapy, it has become the market's dominating category.

Brachytherapy Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa

• South Africa
• GCC Countries
• Rest of the Middle East & Africa (ME&A)

Brachytherapy Market Regional Analysis

For several reasons, North America led the global brachytherapy market. This popularity can be linked to the advantages that brachytherapy provides over older approaches, such as increased safety and efficiency in cancer treatment. In 2023, there are expected to be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States. Healthcare reforms in the United States have improved population access and coverage, with the goal of increasing the healthcare system's overall effectiveness.

In the Asia-Pacific region, the brachytherapy market is projected to experience the highest compound annual growth rate due to higher prevalence of cancer cases. For instance, cancer cases in India are expected to reach 1,496,972 in 2023, up from 1,461,427 in 2022, according to the minister.

In Europe, the EU Science Hub expected a high rise in new cancer cases due to demographics. Radiotherapy is anticipated to be the preferred treatment option in these cases. Radiotherapy also plays a crucial role in the effective treatment of most tumors in middle and low-income countries, contributing to the expected growth of the brachytherapy market in the near future.

Brachytherapy Market Players

Some of the top brachytherapy companies offered in our report include Theragenics Corporation, Varian Medical Systems, Inc., Eckert & Ziegler BEBIG, Becton, Dickinson and Company, iCAD, Inc., Elekta AB, Isoray Medical, Inc., and CIVCO Medical Solutions.